Slide Ferghana is A Leading OUR SECTOR EXPERTISE OUR TRANSACTIONAL EXPERTISE
We deliver high quality, senior level advice to the Life Sciences sector
for value-added Corporate Partnering, M&A and Financing Transactions. Life Science Investment Bank Slide Ferghana is A Leading OUR SECTOR EXPERTISE OUR TRANSACTIONAL EXPERTISE
We deliver high quality, senior level advice to the Life Sciences sector
for value-added Corporate Partnering, M&A and Financing Transactions. Life Science Investment Bank

Ferghana is A Leading
Life Science Investment Bank

We deliver high quality, senior level advice to the Life Sciences sector for value-added Corporate Partnering, M&A and Financing Transactions.

OUR SECTOR EXPERTISE

OUR TRANSACTIONAL EXPERTISE

Ferghana Partners

Ferghana is a leading, “content strong” investment banking firm servicing the Life Sciences sector; specializing in the healthcare and specialty chemicals sectors. The company consistently meets and exceeds its clients’ high expectations.

Learn more

Transactional Expertise

Ferghana clients expect delivery of high quality, senior-level transactional advice to the global life science sector. The company creates and executes strategic transactions for growth or to maximize shareholder value.

ACQUISITIONS

DIVESTMENTS

CORPORATE PARTNERING

CORPORATE PARTNERING

FINANCINGS

FINANCINGS

Select Transactions

We deliver high quality, senior level advice to the global Life Sciences sectors
for value ­added Corporate Partnering, M&A and Financing Transactions.

Acquisition

Acquisition

In August 2009, Ferghana served as the sole advisor to Cephalon (Frazer, PA) on the acquisition of Arana Therapeutics (Sydney, Australia). Cephalon acquired Arana in order to advance its inflammatory disease and oncology pipeline. The transaction catalyzed Cephalon’s entrance into the biologics space.

Cephalon(now part of Teva) was a global biopharmaceutical company engaged in discovery, development and commercialization of unique therapeutic products. The company focused on four main therapeutic areas: central nervous system, inflammatory diseases, pain and oncology.

The Arana acquisition provided Cephalon with an established protein engineering platform to transform proteins, including antibodies, into potent drug candidates. ART621, a Phase II treatment for sciatica/RA, and the lead biologic in Arana’s portfolio, was the first domain antibody to enter the clinic targeting TNF-alpha/RA.

View All Transactions

Cephalon
Partnering

Partnering

AFT Pharmaceuticals (Auckland, New Zealand) is a specialty pharmaceutical company with activities in generic, prescription and OTC markets. The Company has several patented, novel products that it sells in its Home Markets and that it licenses to leading local and regional biopharma centered companies across the world. Ferghana Partners has advised AFT on various partnering deals for Maxigesic®, a fixed dose combination of paracetamol and ibuprofen for use in an OTC or prescription market. These deals have catalyzed the Company’s commercial expansion into 42 countries to date, with more to come.

AFT has an extensive, growing development portfolio of patented OTC and prescription drugs and Orphan Drug Products, in addition to a unique drug delivery device for intranasal delivery of therapeutic agents. Maxigesic® provides significantly more effective pain relief, without the use of codeine, through a proprietary combination of Paracetamol and Ibuprofen.

Ferghana Partners has aided AFT Pharmaceuticals in global expansion through partnering with companies such as Actavis, Angelini, Kern Pharma and Stada. These partnering deals have allowed AFT to access local markets quickly and thoroughly, which include Ibeva, Scandinavia, UK/Ireland, UAE, East/Central Europe, Italy, Turkey etc.

View All Transactions

AFT Pharmaceuticals
Divestment

Divestment

In February 2015, Ferghana advised Signature Diagnostics (Potsdam, Germany) on the Company’s sale to Roche Diagnostics Deutschland (Mannheim, Germany). Roche acquired Signature Diagnostics in an effort to advance translational research to accelerate Roche’s next generation sequencing (NGS) diagnostics.

Signature Diagnostics was a privately held translational oncology and genomics company. Signature collects and curates large blood plasma and tissue biobanks in multiple cancers.  The longitudinal plasma samples from these biobanks are used in the development of next generation assays, including Signature’s OncoDetect assay, which can be used to monitor patients with late stage colorectal cancers using circulating cell-free DNA in blood.

Roche believes that Signature’s high value cancer biobanks that include longitudinal plasma samples from multiple cancers in addition to high-quality NGS assays will allow it to accelerate the development of targeted NGS-based screening assays in the future.

View All Transactions

Signature Diagnostics
Financing

Financing

In October 2012, Ferghana acted as financial advisor to Mirna Therapeutics (Austin, TX) and sole placement agent for its $34.5 million Series C equity financing to advance oncology microRNA pipeline into the clinic. The institutional investment was one of the largest ever for a Texas biotechnology company.

Mirna is a biopharmaceutical company focused on the development and commercialization of microRNA (miRNA) therapeutics in cancer. The funding enabled Mirna to advance its lead microRNA-based therapeutic product candidate, MRX34, through human proof of concept studies. Securing the investment positioned Mirna to become the first company in the biotechnology and pharmaceutical industry to advance any therapeutic agent based on miRNA mimics deeper through the clinical focus on Cancer.

In 2013, MRX34 entered clinical testing, where the product is being studied in a multicenter, open-label Phase 1 clinical trial. The MRX34 Phase 1 clinical study is expected to be completed in late 2015.

View All Transactions

Mirna Therapeutics
VIEW ALL TRANSACTIONS

Our Company Values

GLOBAL

GLOBAL

CONTENT STRONG

CONTENT STRONG

ACCESSIBLE

ACCESSIBLE

RESPONSIVE

RESPONSIVE

Sector Expertise


Ferghana provides advice on corporate partnering/development and ownership/business portfolio topics, such as Mergers, Acquisitions, Joint Ventures and Divestitures to its clients, as well as creating and executing Financial Transactions.

The clients comprise established Specialty Chemical, Pharmaceutical and Diagnostics companies as well as emergent Pharma and Biotechnology companies with a therapeutic or diagnostic focus.


Biotechnology

Biotechnology

Ferghana advises its clients on strategic Partnerships, Acquisitions and Divestments, as well as on creative…

Biotechnology

Diagnostic/Tools

Diagnostic/Tools

lorem ipsum lorem ipsum

Diagnostic/Tools

Medical Device

Medical Device

lorem ipsum lorem ipsum

Medical Device

OTC Drugs

OTC Drugs

lorem ipsum lorem ipsum

OTC Drugs

Pharmaceuticals

Pharmaceuticals

Ferghana advises its clients on strategic Partnerships, Acquisitions and Divestments, as well as on creative…

Pharmaceuticals

Specialty Chemicals

Specialty Chemicals

lorem ipsum lorem ipsum

Specialty Chemicals

Our Reach

Ferghana conveniently has offices and strategic partners around the world.

• Principal Offices
• Secondary Locations

Learn more

Contact Us

CONTACT FERGHANA